6 days Ago By Defense World Staff
Evolus (NASDAQ:EOLS – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $27.00 price target on the stock.
HC Wainwright’s price objective points to a potential upside of 183.02% from the stock’s current price. HC Wainwright also issued estimates for Evolus’ FY2026 earnings at $0.
41 EPS, FY2027 earnings at $1.06 EPS, FY2028 earnings at $2.20 EPS and FY2029 earnings at $3.
60 EPS. Several other equities research analysts also recently weighed in on EOLS. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.
00 price objective on shares of Evolus in a report on Wednesday. Barclays upped their price target on shares of Evolus from $22.00 to $25.
00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th.Read Our Latest Research Report on EOLSEvolus Stock Up 1.4 %EOLS opened at $9.
54 on Thursday. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.
47 and a quick ratio of 2.23. Evolus has a 12 month low of $8.
67 and a 12 month high of $17.82. The stock’s 50 day moving average price is $12.
91 and its 200 day moving average price is $13.33. The stock has a market cap of $606.
62 million, a P/E ratio of -10.48 and a beta of 0.97.
Insider Buying and Selling at EvolusIn other news, insider Rui Avelar sold 27,904 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.
04. Following the completion of the sale, the insider now directly owns 362,467 shares of the company’s stock, valued at $4,806,312.42.
This represents a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Also, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.
40. Following the sale, the insider now directly owns 508,619 shares of the company’s stock, valued at $6,306,875.60.
This trade represents a 1.21 % decrease in their position. The disclosure for this sale can be found here.
In the last three months, insiders sold 60,575 shares of company stock valued at $794,369. 6.10% of the stock is owned by insiders.
Institutional Investors Weigh In On EvolusA number of large investors have recently bought and sold shares of EOLS. Rhumbline Advisers boosted its holdings in shares of Evolus by 4.1% during the 1st quarter.
Rhumbline Advisers now owns 83,436 shares of the company’s stock worth $1,004,000 after buying an additional 3,287 shares during the period. GAMMA Investing LLC boosted its holdings in Evolus by 1,765.9% during the first quarter.
GAMMA Investing LLC now owns 18,622 shares of the company’s stock valued at $224,000 after acquiring an additional 17,624 shares during the period. Jefferies Financial Group Inc. acquired a new stake in shares of Evolus in the fourth quarter valued at about $753,000.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Evolus by 6.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,052 shares of the company’s stock worth $1,270,000 after purchasing an additional 6,821 shares during the period.
Finally, Zimmer Partners LP lifted its position in shares of Evolus by 66.6% during the 4th quarter. Zimmer Partners LP now owns 416,500 shares of the company’s stock worth $4,598,000 after purchasing an additional 166,500 shares during the last quarter.
90.69% of the stock is currently owned by institutional investors. About Evolus (Get Free Report)Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe.
The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.Recommended StoriesFive stocks we like better than EvolusESG Stocks, What Investors Should KnowJPMorgan is a Buy, if You Can Handle The Volatility What is a Low P/E Ratio and What Does it Tell Investors?United States Steel’s Crash: An Unmissable Buying OpportunityThe Significance of Brokerage Rankings in Stock SelectionRocket Lab Stock: Weathering the Storm, Time for a Comeback?.
